This June 1–7, we recognize and raise awareness of hidradenitis suppurativa (HS) — the chronic inflammatory skin condition that affects an estimated 1% of the world’s population. Causing painful nodules,
The FDA has approved Differin® Epiduo® Acne Gel (adapalene 0.1% and benzoyl peroxide 2.5%) for over-the-counter (OTC) use in patients aged 12 years and older with acne. The prescription-to-OTC switch
A large population-based study from the Baltimore Longitudinal Study of Aging (BLSA) offers new insight into some of the key factors associated with stronger skin barrier function. The study, published
In a decision that expands the April 2025 approval of dupilumab (Dupixent, Regeneron/Sanofi) for chronic spontaneous urticaria (CSU) in adults and adolescents aged 12 years and older, the U.S. Food
The American Academy of Dermatology (AAD) has, for the first time, issued guidelines of care for the medical management of pediatric eczema. Commonly known as pediatric atopic dermatitis (AD), this
A plant-based ingredient used in Chinese medicine for more than 2,000 years may offer therapeutic anti-aging properties, along with a range of skin benefits, including collagen support, antioxidant activity, and
A recent paper published in Frontiers in Drug Discovery examines the potential of bispecific and trispecific biologics (multi-specific biologics), a new class of therapies in development for atopic dermatitis (AD).
As scientific and technological capabilities continue to advance, the U.S. Food and Drug Administration (FDA) is easing a long-standing drug approval requirement for common diseases. Rather than requiring drugmakers to
The FDA’s approval of deucravacitinib (Sotyktu; Bristol Myers Squibb) for the treatment of adults with active psoriatic arthritis (PsA), marks the first approval of a tyrosine kinase 2 (TYK2) inhibitor
The recent FDA approval of icotrokinra (Icotyde; Johnson & Johnson), a first-in-class oral interleukin-23 (IL-23) receptor antagonist, has potentially opened the door to a new way of treating moderate-to-severe plaque
The FDA’s approval of a new weight-based secukinumab (Cosentyx) formulation offers adolescents with moderate-to-severe hidradenitis suppurativa (HS) a new treatment option for the condition, also known as acne inversa. A chronic inflammatory skin disease
The National Psoriasis Foundation (NPF) has issued a new position statement on psoriasis disease severity that clarifies the definition of severity in an effort to increase access to systemic therapy
Data from a recent trial of EVO301, a long-acting injectable interleukin-18 binding protein, show that the anti-IL-18 protein was effective for the treatment of moderate-to-severe atopic dermatitis (AD) in adults.
The popularity of GLP1 medications in the United States has increased significantly, driven by their effectiveness in weight management and diabetes treatment. The market potential for these drugs is substantial,
The regenerative movement is gaining momentum, harnessing the body’s natural healing processes to repair or replace damaged skin tissue, and dermatology professionals are embracing exciting new therapies and procedures. Guided
Off-label use — prescribing a medication for an indication, patient population, dose, or route not specifically approved by regulatory agencies — is a legal and widely accepted practice in dermatology
The U.S. Food and Drug Administration (FDA) has accepted the resubmission of a Biologics License Application (BLA) for relabotulinumtoxinA (Relfydess), a next-generation neuromodulator under review for the temporary improvement of
Originally developed for the treatment of type 2 diabetes, GLP-1 receptor agonists (GLP-1 RAs) have more recently been used in obesity management and metabolic disease. Emerging research now suggests that
The FDA’s recent report evaluating the use of perfluoroalkyl and polyfluoroalkyl substances (PFAS) in cosmetic products revealed significant uncertainty due to gaps in existing data on PFAS exposure through cosmetics.
As consumers continue to lean into self-care and wellness trends, the nail care industry is expanding, with a 2024 global market value of $8.8 billion that is forecasted to keep
Sign up to receive updates on educational opportunities, complimentary content, exclusive discounts, and more.
Sign up to receive updates on educational opportunities, complimentary content, exclusive discounts, and more.
